American Well director Slavin to resign in 2026

American Well Corporation reports that board member Dr. Peter Slavin has notified the company he will resign from its Board of Directors, effective at the company’s next annual meeting of stockholders in 2026.

Accepted by SEC EDGAR 04/02/2026 - 05:06 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

American Well Corporation reports that board member Dr. Peter Slavin has notified the company he will resign from its Board of Directors, effective at the company’s next annual meeting of stockholders in 2026. He will continue to serve as a director until that meeting.

The company states that Dr. Slavin’s decision is due to his transition to a new role on the West Coast of the United States and is not the result of any disagreement regarding American Well’s operations, policies, or procedures. The company expresses appreciation for his more than nine years of board service.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Terms

Emerging growth company, Board of Directors, annual meeting of stockholders, Item 5.02

4 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Board of Directors financial

"he will resign from the Board of Directors, effective on the date"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

annual meeting of stockholders financial

"effective on the date of the Company’s next annual meeting of stockholders"

Item 5.02 regulatory

"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"

Item 5.02 is a specific disclosure category on the U.S. Securities and Exchange Commission’s Form 8‑K that requires public companies to report changes in key personnel and related compensation arrangements. It covers departures and appointments of directors and certain officers, elections of directors, and new or material changes to compensatory agreements for those persons; the company must file a Form 8‑K with the required information and any related exhibits within the SEC’s prescribed reporting timeframe. The item is a rule‑based reporting obligation under U.S. securities law, so its scope and timing follow the SEC’s definitions and deadlines rather than informal usage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is American Well (AMWL) director Dr. Peter Slavin resigning?

Dr. Peter Slavin is resigning from American Well’s Board because he is transitioning to a new role on the West Coast. The company states his decision is not due to any disagreement over operations, policies, or procedures.

When will Dr. Peter Slavin’s resignation from American Well (AMWL) take effect?

His resignation will be effective at American Well’s next annual meeting of stockholders in 2026. Until that meeting occurs, he will continue to serve as a member of the Board of Directors.

Does Dr. Slavin’s resignation signal a dispute with American Well (AMWL)?

The company explicitly states Dr. Slavin’s resignation is not due to any disagreement with American Well. It clarifies there are no disputes regarding operations, corporate policies, or procedures behind his decision to leave the Board.

How long has Dr. Peter Slavin served on American Well’s (AMWL) Board?

American Well notes that Dr. Slavin has served on its Board of Directors for more than nine years. The company publicly thanks him for this extended period of service and his contributions to the organization.

What form did American Well (AMWL) use to disclose Dr. Slavin’s resignation?

American Well disclosed Dr. Slavin’s planned resignation in a Form 8-K. The filing falls under Item 5.02, which covers departures and appointments of directors or certain executive officers and related compensatory arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001393584false00013935842026-04-012026-04-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 01, 2026

American Well Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39515	20-5009396
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
75 State Street Ste. 100
Boston, Massachusetts				02109
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 204-3500

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.01 Par Value		AMWL		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, Dr. Peter Slavin notified American Well Corporation (the “Company”) that he will resign from the Board of Directors, effective on the date of the Company’s next annual meeting of stockholders to be held in 2026. Dr. Slavin will continue to serve as a director until such meeting. Dr. Slavin’s decision to resign results from his transition to a new role on the West Coast of the United States, and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or procedures. The Company thanks Dr. Slavin for his more than nine years of service as a member of the Company’s Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AMERICAN WELL CORPORATION
Date:	April 2, 2026	By:	/s/ Anna Nesterova
			Anna Nesterova Deputy General Counsel, Head of Legal

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.3 KB